Neuromuscular complications in cancer

Grisold, Wolfgang; Grisold, Anna; Löscher, Wolfgang N.

doi:10.1016/j.jns.2016.06.002

Cited by 18 publications

(7 citation statements)

References 326 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This weight loss is associated with impaired muscle strength and functional performance (Couch et al 2015), reduced health-related quality of life (HRQL) (Orell-Kotikangas et al 2017), and an increased perception of fatigue (Couch et al 2007). Together, these impairments can impact physical capabilities, substantially diminish functional independence and may be accompanied by several neuromuscular complications associated with cancer (for a review, see Grisold et al 2016).…”

Section: Introductionmentioning

confidence: 99%

Neuromuscular function and fatigability in people diagnosed with head and neck cancer before versus after treatment

Lavigne¹,

Lau²,

Francis³

et al. 2019

Preprint

View full text Add to dashboard Cite

Purpose: Treatment for head and neck cancer is associated with multiple side-effects, including loss of body mass, impaired physical function, and reduced health-related quality of life. This study aimed to investigate the impact of treatment (radiation therapy ± concurrent chemotherapy) on (i) muscle strength, muscle cross-sectional area and patient-reported outcomes, and (ii) central and peripheral alterations during a whole-body exercise task.Methods: Ten people with head and neck cancer (4 female; 50±9 years) completed a lab visit before and after (56±30 days) completion of treatment. Participants performed a neuromuscular assessment (involving maximal isometric voluntary contractions in the knee extensors and electrical stimulation of the femoral nerve) before and during intermittent cycling to volitional exhaustion. Anthropometrics and patient-reported outcomes were also assessed.Results: From before to after treatment, maximal isometric muscle strength was reduced (P=0.002, d=0.73), as was potentiated twitch force (P<0.001, d=0.62), and muscle cross-sectional area (e.g. vastus lateralis: P=0.010, d=0.64). Exercise time was reduced (P = 0.008, d = 0.62) and peripheral processes contributed to a reduction in maximal force due to cycling. After treatment, the severity of self-reported fatigue increased (P=0.041, r=-0.65) and health-related quality of life decreased (P=0.012, r=-0.79).Conclusion: Neuromuscular function was impaired in patients with head and neck cancer after treatment. Whole-body exercise tolerance was reduced and resulted in predominantly peripheral, rather than central, disturbances to the neuromuscular system. Future research should evaluate strength training after treatment for head and neck cancer, with the overall aim of reducing fatigue and improving health-related quality of life.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuromuscular function and fatigability in people diagnosed with head and neck cancer before versus after treatment

Lavigne¹,

Lau²,

Francis³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Paraneoplastic Neurological Disorders (PNDs) are remote effects of systemic malignancies that affect the nervous system 1,2 . PNDs are relatively rare compared to metastatic and iatrogenic complications of cancer, and overall affect fewer than 1% of patients with cancer 3 .…”

Section: Introductionmentioning

confidence: 99%

Enfermedad de motoneurona asociada a procesos neoplásicos: una revisión de casos

Rocha¹,

Ribeiro²,

Correia³

et al. 2021

Gal. Clin.

View full text Add to dashboard Cite

To do a retrospective analysis of all patients with MND in our cohort who had an associated tumour.2) Verify if there is any correlation between treatment of the underlying tumour and improvement of MND in those patients. METHODSWe analysed through a 4-year retrospective study, from January 2013 to December 2016, the files of patients with an active MND (of every subtype) in our Hospital (N= 35). The hospital total referral population is 315 000 inhabitants. There was no need of approval of ethic committee due to being a retrospective study and no intervention was made. Clinical and electrophysiological examination (EMG) was performed in all patients. Awaji criteria 11 were applied for Clinical and Electrophysiological diagnosis of MND. An active search for a primitive tumour was made as part of the investigation for treatable causes of MND, according to EFNS 2012 Guidelines 12 . CASES REPORT/RESULTSA neoplastic process was found in four (11,4%) of our MND patients (table 1). Case 1 is a 55-year-old female, refered for breast tumorectomy and radiotherapy in 2005 due to invasive ductal breast cancer (IDBC), which was BRCA2 mutation-related. The IDBC ABSTRACT Introduction: Association between Motor Neuron Disease (MND) and neoplastic processes is rarely described. It is unclear whether MND occurs as a paraneoplastic syndrome. Methods: We retrospectively analysed 35 patients with MND followed in our Hospital from January 2013 to December 2016. Results: A neoplastic process was found in four patients. All of them had definite clinical and electromyographic criteria supporting MND according to standard Awaji criteria. Results: Onconeuronal antibodies were positive in two patients (anti-Yo and anti-PNMA2). The types of tumour were variable: two breast cancers, one lung cancer and one thyroid Hürthle cell neoplasm. Discussion: In our cohort, 11.4% of MND patients were diagnosed with a neoplastic process being a rather high frequency of co-occurrence. Treating the neoplastic process may potentially halt or reverse the progression of MND.

show abstract

“…Once chronic OIPN progresses, sensory ataxia becomes evident manifesting with difficulty in manipulating small objects (particularly if not looking at them), standing unless base widening, and in general in all those situations where the effective balance due to proprioceptive input cannot be compensated by visual input, such as in poorly lit environments. Only anecdotally cranial, autonomic, or motor nerve impairment has been reported as a consequence of OHP administration [8].…”

Section: Introductionmentioning

confidence: 99%

Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy

Cavaletti

Marmiroli

2020

Cancers

View full text Add to dashboard Cite

Oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe and potentially permanent side effect of cancer treatment affecting the majority of oxaliplatin-treated patients, mostly with the onset of acute symptoms, but also with the establishment of a chronic sensory loss that is supposed to be due to dorsal root ganglia neuron damage. The pathogenesis of acute as well as chronic OIPN is still not completely known, and this is a limitation in the identification of effective strategies to prevent or limit their occurrence. Despite intense investigation at the preclinical and clinical levels, no treatment can be suggested for the prevention of OIPN, and only limited evidence for the efficacy of duloxetine in the treatment setting has been provided. In this review, ongoing neuroprotection clinical trials in oxaliplatin-treated patients will be analyzed with particular attention paid to the hypothesis leading to the study, to the trial strengths and weaknesses, and to the outcome measures proposed to test the efficacy of the therapeutic approach. It can be concluded that (1) prevention and treatment of OIPN still remains an important and unmet clinical need, (2) further, high-quality research is mandatory in order to achieve reliable and effective results, and (3) dose and schedule modification of OHP-based chemotherapy is currently the most effective approach to limit the severity of OIPN.

show abstract

Neuromuscular complications in cancer

Cited by 18 publications

References 326 publications

Neuromuscular function and fatigability in people diagnosed with head and neck cancer before versus after treatment

Neuromuscular function and fatigability in people diagnosed with head and neck cancer before versus after treatment

Enfermedad de motoneurona asociada a procesos neoplásicos: una revisión de casos

Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy

Contact Info

Product

Resources

About